Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.44 |
| ▸ | METAP1 | P53582 | 1/20 | 0.44 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.37 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.35 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.32 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.31 |
| ▸ | ITGAV | P06756 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.30 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.30 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.30 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9936013 | 0.81 | METAP2 (0.44) | METAP2METAP1NPY5RENPP1ITGB3 | |
| SCHEMBL4957462 | 0.81 | METAP2 (0.44) | METAP2METAP1NPY5RENPP1ITGB3 | |
| SCHEMBL9572857 | 0.81 | METAP2 (0.44) | METAP2METAP1NPY5RENPP1ITGB3 | |
| SCHEMBL10857663 | 0.81 | METAP2 (0.44) | METAP2METAP1NPY5RENPP1ITGB3 | |
| SCHEMBL4957389 | 0.81 | METAP2 (0.44) | METAP2METAP1NPY5RENPP1ITGB3 | |
| SCHEMBL1193887 | 0.81 | METAP2 (0.44) | METAP2METAP1NPY5RENPP1ITGB3 | |
| SCHEMBL4955472 | 0.79 | METAP2 (0.42) | METAP2METAP1NPY5RENPP1ITGB3 | |
| SCHEMBL30884953 | 0.79 | METAP2 (0.42) | METAP2METAP1NPY5RENPP1ITGB3 | |
| SCHEMBL29208955 | 0.79 | METAP2 (0.42) | METAP2METAP1NPY5RENPP1ITGB3 | |
| SCHEMBL9569994 | 0.79 | METAP2 (0.42) | METAP2METAP1NPY5RENPP1ITGB3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111132721-B | Multiple-inflation type intravascular medical device | W.L.戈尔及同仁股份有限公司 | 2022-07-19 | — | — | CN | disclosed |
| CN-109689692-B | Bispecific antibodies and antibody conjugates for tumor therapy and uses thereof | 本康生物制药（深圳）有限公司 | 2021-11-12 | — | — | CN | disclosed |
| CN-110651996-A | Food for nourishing and improving kidney function and preparation method thereof | 马晨光 | 2020-01-07 | — | — | CN | disclosed |
| CN-104017746-B | Lactobacillus, composition thereof and application of lactobacillus in preparation of medicines for treating heart and liver diseases caused by lupus erythematosus | 景岳生物科技股份有限公司 | 2017-08-22 | — | — | CN | disclosed |
| CN-104017746-A | Lactobacillus, compositions thereof and use for treating autoimmune diseases and complications | GENMONT BIOTECH INC | 2014-09-03 | — | — | CN | disclosed |
| US-20110251172-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. | 2011-10-13 | — | — | US | disclosed |
| EP-2312945-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | Merck Sharp & Dohme Corp. (US) | 2011-04-27 | — | — | EP | disclosed |
| WO-2010019392-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. (US) | 2010-02-18 | — | — | WO | disclosed |
| EP-1176959-B1 | NOVEL PROLINES AS ANTIMICROBIAL AGENTS | MERCK & CO INC (US) | 2006-03-08 | — | — | EP | disclosed |
| US-6579894-B2 | Bactericides, fungicides | MERCK & CO., INC. | 2003-06-17 | — | — | US | disclosed |
| US-20030013724-A1 | Novel prolines as antimicrobial agents | HAMMOND MILTON L (US) | 2003-01-16 | — | — | US | disclosed |
| US-6417217-B1 | TREATING INFECTIONS WITH HETEROCYCLIC MICROBIOCIDES THIS INVENTION RELATES TO THE FIELD OF TRANSFER RIBONUCLEIC ACID (TRNA) SYNTHETASE INHIBITORS, THEIR PREPARATION AND THEIR USE AS ANTIMICROBIAL ADMINISTERING TO THE SUBJECT A | MERCK & CO., INC. | 2002-07-09 | — | — | US | disclosed |
| US-6333344-B1 | ENZYME INHIBITORS AND BACTERICIDES | MERCK & CO. | 2001-12-25 | — | — | US | disclosed |
| EP-0562832-A1 | Indole and indazole derivatives, for the treatment and prophylaxis of cerebral disorders, their preparation and their use | SANKYO COMPANY LIMITED (JP) | 1993-09-29 | — | — | EP | disclosed |
| EP-0069507-A2 | Hydrocarbon compositions containing heteroaromatic nitrogen compounds | EXXON RESEARCH AND ENGINEERING COMPANY (US) | 1983-01-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030013724-A1 | Novel prolines as antimicrobial agents | AARS1, EPRS1, TRMT1 | METAP2 1792/4885METAP1 1404/4885CACNA1H 4769/4885 |
| US-20110251172-A1 | PURINE DERIVATIVES FOR TREATMENT OF ALZHEIMER'S DISEASE | BACE1, APP, PSEN1 | METAP2 295/4885METAP1 179/4885CACNA1H 3098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.